Drug Approval | November 14, 2025
Alembic receives USFDA final approval for Dexlansoprazole delayed-release capsules, 30 mg and 60 mg
Dexlansoprazole delayed-release capsules are a proton pump inhibitor
Dexlansoprazole delayed-release capsules are a proton pump inhibitor
The FDA is initiating removal of the boxed warnings following a comprehensive review of the scientific literature
Nearly 1 in 3 HbA1c test results fall within the diabetic range, while 1 in 4 individuals show signs of prediabetes
Patients on baxdrostat showed a significant reduction in systolic blood pressure (SBP) compared to placebo
The device delivers clear, high-quality images to support accurate diagnoses across a broad range of patient groups
The study demonstrated strong clinical outcomes, with 94.8 per cent of subjects remaining free from major target limb amputation at one year
The company has introduced an innovative Dual Release Proton Pump Inhibitor (PPI) tablet, a next-generation therapy for patients suffering from moderate to severe or treatment resistant gastroesophageal reflux disease
Building on the Merck Foundation’s longstanding commitment to advancing access to high-quality health care, new national initiative supports grants to 11 organizations across the country
The upcoming state-of-the art 400+ bed facility is set to come up at an approximate cost of Rs 500 crore
AI-powered cardiometabolic wellness platform for India’s workforce
Subscribe To Our Newsletter & Stay Updated
